Anne-Sophie Romain

Anne-Sophie Romain

Auto-generated profile, based on publicly available information

Anne-Sophie Romain

Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Trousseau Hospital, General Paediatrics Department, 75012 Paris, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MOMarie-Hélène Odièvre
Marie-Hélène Odièvre
CMCharles de Marcellus
Charles de Marcellus
HPHubert Ducou Le Pointe
Hubert Ducou Le Pointe
SASlimane ALLALI
Slimane ALLALI
ARAnne‐Sophie Romain
Anne‐Sophie Romain
HCHarriet Corvol
Harriet Corvol
Click on the article title to read more.

18 September 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
BMBenoît Manfroi
Benoît Manfroi
BCBui Thi Cuc
Bui Thi Cuc
ASAurélien Sokal
Aurélien Sokal
AVAlexis Vandenberghe
Alexis Vandenberghe
STSarah Temmam
Sarah Temmam
SFSimon Fillatreau
Simon Fillatreau
The development of the human immune system lasts for several years after birth. The impact of this maturation phase on the quality of adaptive immunity and the acquisition of immunological memory after infection at a young age remains incompletely defined. Here, using an antigen-reactive T cell (ARTE) assay and multidimensional flow cytometry, we profiled circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–reactive CD3 + CD4 + CD154 + T cells in children and adults before infection, during infection, and 11 months after infection, stratifying children into separate age groups and adults according to disease severity. During SARS-CoV-2 infection, children younger than 5 years old displayed a lower antiviral CD4 + T cell response, whereas children older than 5 years and adults with mild disease had, quantitatively and phenotypically, comparable virus-reactive CD4 + T cell responses. Adults with severe disease mounted a response characterized by higher frequencies of virus-reactive proinflammatory and cytotoxic T cells. After SARS-CoV-2 infection, preschool-age children not only maintained neutralizing SARS-CoV-2–reactive antibodies postinfection comparable to adults but also had phenotypically distinct memory T cells displaying high inflammatory features and properties associated with migration toward inflamed sites. Moreover, preschool-age children had markedly fewer circulating virus-reactive memory B cells compared with the other cohorts. Collectively, our results reveal unique facets of antiviral immunity in humans at a young age and indicate that the maturation of adaptive responses against SARS-CoV-2 toward an adult-like profile occurs in a progressive manner.

31 October 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
LBLaura Berdah
Laura Berdah
ARAnne-Sophie Romain
Anne-Sophie Romain
SRSimon Rivière
Simon Rivière
ASAurélie Schnuriger
Aurélie Schnuriger
MPMarine Perrier
Marine Perrier
HCHarriet Corvol
Harriet Corvol
Objectives Acute bronchiolitis is a major public health issue with high number of infants hospitalised worldwide each year. In France, hospitalisations mostly occur between October and March and peak in December. A reduction of emergency visits for bronchiolitis has been observed at onset of the COVID-19 outbreak. We aimed to assess the pandemic effects on the hospitalisations for bronchiolitis during the 2020–2021 winter (COVID-19 period) compared with three previous winters (pre-COVID-19). Design Retrospective, observational and cross-sectional study. Setting Tertiary university paediatric hospital in Paris (France). Participants All infants aged under 12 months who were hospitalised for acute bronchiolitis during the autumn/winter seasons (1 October to 31 March) from 2017 to 2021 were included. Clinical and laboratory data were collected using standardised forms. Results During the COVID-19 period was observed, a 54.3% reduction in hospitalisations for bronchiolitis associated with a delayed peak (February instead of November–December). Clinical characteristics and hospitalisation courses were substantially similar. The differences during the COVID-19 period were: smaller proportion of infants with comorbidities (8% vs 14% p=0.02), lower need for oxygen (45% vs 55%, p=0.01), higher proportions of metapneumovirus, parainfluenzae 3, bocavirus, coronavirus NL63 and OC43 (all p≤0.01) and no influenza. The three infants positive for SARS-CoV-2 were also positive for respiratory syncytial virus, suggesting that SARS-CoV-2 alone does not cause bronchiolitis, despite previous assumptions. Conclusion The dramatic reduction in infants’ hospitalisations for acute bronchiolitis is an opportunity to change our future habits such as advising the population to wear masks and apply additional hygiene measures in case of respiratory tract infections. This may change the worldwide bronchiolitis burden and improve children respiratory outcomes.

11 September 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
AFApolline Furgier
Apolline Furgier
CBCamille Brehin
Camille Brehin
CLCorinne Levy
Corinne Levy
RBRomain Basmaci
Romain Basmaci
ELElise Launay
Elise Launay
SWSebastien Walser
Sebastien Walser
Nirsevimab was first introduced in September 2023, showing strong real-world effectiveness in preventing hospitalised RSV-bronchiolitis. RSV-A circulation predominated during 2023–2024, whereas RSV-B was frequent in 2024–2025. Recent reports indicated resistance to nirsevimab in RSV-B strains in France. We aimed to assess the effectiveness of large-scale nirsevimab implementation against hospitalised RSV-bronchiolitis during high RSV-B circulation. A test-negative case-control study was conducted using a national hospital-based surveillance system. All children <12 months hospitalised for bronchiolitis and tested for RSV in 12 French hospitals from October 10, 2024 to March 15, 2025, were included. Cases were RSV-positive bronchiolitis; controls were RSV-negative bronchiolitis. Effectiveness was assessed by a multivariable logistic regression model adjusted for confounders (sex, gestational age at birth, birth weight, risk factors for severe bronchiolitis, month of diagnosis, and medical centre). A range of sensitivity analyses was conducted. 1270 patients were included; among which 830 (65.3%) were RSV-positive and 440 (34.7%) were RSV-negative bronchiolitis. The male-to-female sex ratio was 1.35, and the median age was 3 months (IQR: 1.5–5.6). Among cases, 182 (22.0%) received nirsevimab, compared to 282 (64.1%) for controls. Adjusted effectiveness against RSV-bronchiolitis was 84.9% (95% CI, 80.0–88.6). Subgroup analyses by age and severity (intensive care unit admission, respiratory support) showed consistent results, along with sensitivity analyses. Despite high RSV-B circulation, which has recently been identified to carry mutations potentially inducing resistance to nirsevimab, the effectiveness of the second national nirsevimab campaign against hospitalisation for RSV-bronchiolitis remained high. The study received financial support from 10.13039/100031283 Sanofi , 10.13039/501100014088 AstraZeneca , and the 2023 ATIP-Avenir grant from the 10.13039/501100001677 National Institute of Health and Medical Research (Inserm) .